Remove Pharma Companies Remove Research Remove Research Analyst
article thumbnail

Risk sharing agreements soar as market access risk increases

Pharmaceutical Technology

Over the last twenty years, there has been a major rise in risk sharing agreements in the pharmaceutical space, said Alex Watt, GlobalData’s principal research analyst, at a recent webinar on the same topic. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies.

Marketing 257
article thumbnail

Eli Lilly, Pfizer, Merck among Big Pharma losers in China's latest round of procurement bidding

The Pharma Data

Companies such as AstraZeneca, Sanofi and Eli Lilly have managed to keep business under the aggressive procurement program, but they had to live with major discounts. . It’s not a completely unforeseen shift, though. Pfizer’s established drugs business started showing a decline in China back in April 2019.

article thumbnail

Subcutaneous Biologics Market Analysis: Current Trends and Future Outlook

Roots Analysis

This has led to the growing research and development towards the development of biologics for therapy purpose. To know more details on the market opportunity for subcutaneous biologics market, visit here >> [link] Author bio Dakshita has been working as a competent business research analyst since she joined Roots Analysis in 2023.